October 1, 2021 8:03am

Remember, earnings will ripen the stocks to be harvested before they rot

The Biostage (BSTG) Chronicle: negligence? <read more>

Pre-open indications: 1 BUYs and 4 SELLs

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.31% (+106 points), S&P futures are UP +0.28% (+13 point) and NASDAQ futures are UP +0.24% (+37 point)

 

Stock futures pointed to a positive open for the market in an early morning rebound to start October

European markets declined starting Q4   

Asia-Pacific stocks declined with shares in Japan leading losses while markets in Hong Kong were closed for a holiday on Friday and those in mainland China are closed for the Golden Week holiday from Friday till October 7.

 

Henry’omics:

U.S. futures pointed to opening losses in early premarket trading.

Treasury yields slip to start October as investors await data on core inflation, manufacturing and consumer sentiment

The market just capped a tumultuous September as our sector within my coverage group closed basically even with 1 holiday, 10 positive and 10 negative closes.

 

Economic data Docket: key inflation data

  • The core personal consumption expenditures price index, the inflation measure the Federal Reserve uses to set policy, is expected to rise 0.2% in August and 3.5% year over year

 

If you didn’t remember what happen at Thursday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q4: starts today

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Maintaining SELL:

The “pump/promote” is back …

Thursday closed down -$0.02 with 6, 030 shares traded following Wednesday closed down -$0.72 with 1,273 shares traded, Tuesday closed up +$0.48 with 1,251 shares traded, Monday closed flat with 135 shares traded, Friday closed flat at 3.26 with 62 shares traded, Thursday closed up +$0.06 with 839 shares traded, and last Wednesday closed down -$0.45 with 3,833 shares traded, the previous Tuesday’s +$0.25 with 654 shares traded and Monday closing down -$0.26 to $3.40 with 563 shares traded.

  • Will legal fees to defend the terminal death suit going to bankrupt the company now, that costs will not be covered by insurance?
  • The largest issue was NOT providing the documents to the other attorneys as a sanction was put-on and
  • Hong Yu - president, Shunfu Hu and Linghui Meng V.P.'s of what - NEGLIGENCE ... they SHOULD/MUST RESIGN, where is William (BILL) Fodor PhD - CSO, the overseer of a non-happening clinical trial after 1 year and 6 months of approval!

The Biostage (BSTG) Chronicles: wrongful death law suit, insurance claim denied … https://www.regmedinvestors.com/articles/12110

 

SELL from BUY:

bluebird bio (BLUE) closed up +$0.13 to $19.11 after Wednesday’s -$0.62 to $18.98, Tuesday’s $19.60 and Monday’s $19.33 with a negative -$0.61 or -3.19% pre-market indication

 

BUY:

Intellia Therapeutics (NTLA) closed down again -$3.41 to $134.14 following Wednesday’s -$1.85 to $137.56, Tuesday’s $139.41 and Monday’s $147.58 with a positive +$0.85 or +0.63% pre-market indication.

 

Maintaining SELL:

Global Blood Therapeutics (GBT) closed down again -$0.32 to $25.48 following Wednesday’s -$0.75 to $25.80, Tuesday’s +$0.65 to $26.22, Monday’s $26.22 with a negative -$0.18 or -0.71% pre-open indication.

uniQure NV (QURE) closed up +$0.50 to $32.01 with a negative -$1.01 or -3.16% pre-market indication.

 

The BOTTOM LINE: New month and quarter, this week does not end the continuous impact of volatility.

Not yielding in my thoughts, I keep reinforcing that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure to electronic trading risks.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.